HHS finalizes rule on 340B Administrative Dispute Resolution process

Apr 18, 2024 - 02:36 PM
340B-update-900x400

The Department of Health and Human Services April 18 finalized its rule to establish a 340B Administrative Dispute Resolution process as required under the Affordable Care Act. The rule establishes an ADR process that allows all 340B covered entities, regardless of the size of the organization or monetary value of the claim, to avail themselves of this important process to address claims at dispute with drug companies.  

Specifically, the new finalized ADR process would:

  • Create a more conventional administrative process that is less trial-like consisting of 340B program subject matter experts from the Health Resources and Services Administration’s Office of Pharmacy Affairs.
  • Allow covered entities to bring forth claims where they have been overcharged by a drug company including where the drug company or its wholesaler denies access to 340B pricing.
  • Allow claims for ADR panel review even if the particular issue at stake is subject to concurrent federal court review.
  • Require decisions be reached by the ADR process within one year of submission of claims for ADR review.
  • Include a reconsideration process for parties dissatisfied with the 340B ADR panel decision.

In a statement shared with the media, AHA General Counsel Chad Golder said, “The Administration’s final rule for the 340B drug pricing program administrative dispute resolution (ADR) process is an important step in ensuring the integrity of the 340B program. The final rule contains several important process improvements, including a clear timeline for when ADR decisions must be made and an opportunity for reconsideration when parties are dissatisfied with the initial ADR decision. The AHA is particularly pleased that the final rule makes clear that an overcharge claim includes instances where a drug company has limited a hospital’s ability to purchase 340B drugs at or below the 340B ceiling price. This rule will help hold drug companies accountable for their rampant abuses of the 340B program and the patients it serves.

“We look forward to working with the Department of Health and Human Services to make sure it continues to use all tools available to stop drug companies from preventing 340B hospitals from providing vital care to their patients.”

The rule will be effective 60 days from publication in tomorrow’s Federal Register.

Related News Articles

Headline
AHA urges HRSA to act as Eli Lilly threatens 340B discounts over claims data submission policy
The AHA again is asking the Health Resources and Services Administration to take action after Eli Lilly warned hospitals that they could lose access to…
Headline
Washington Post publishes AHA letter in response to anti-340B editorial
The Washington Post yesterday published a letter to the editor from AHA President and CEO Rick Pollack responding to an April 18 editorial criticizing the 340B…
Headline
AHA urges HRSA to abandon 340B rebate model that will cost billions and jeopardize access to care for millions
The Health Resources and Services Administration should abandon its consideration of a 340B rebate model pilot program because “a rebate mechanism of any kind…
Headline
AHA urges en banc review of 4th Circuit’s West Virginia 340B contract pharmacy law decision
The AHA and others April 17 filed an amicus brief requesting the U.S. Court of Appeals for the 4th Circuit grant en banc review of a panel decision that…
Headline
Mississippi 340B law upheld by appeals court in two cases
The U.S. Court of Appeals for the 5th Circuit April 9 affirmed rulings by a Mississippi district court that rejected requests by Novartis and PhRMA to enjoin…
Headline
Court strikes HRSA 340B policy restricting initial hospital drug purchases through GPOs
The U.S. District Court for the District of Columbia March 31 vacated a Health Resources and Services Administration policy instituted in 2013 that restricted…